Medtronic and Eli Lilly Announce Drug-Device Collaboration for Parkinson’s Disease

April 2011 Monthly Message

- He Did It His Way: PAN’s Chairman of the Board on Business, Philanthropy, and Opportunity
- Turning a Difficult Meeting into a Successful Advocacy Experience
- Medtronic and Eli Lilly Announce Drug-Device Collaboration for Parkinson’s Disease
- April is Parkinson’s Awareness Month
- PAN Advocate Jean Burns Given Bonander Award at Unity Walk
- PAN Director of Development / Individual Giving Featured on Comcast Newsmakers
- SAVE THE DATE – 2011 Morris K. Udall Awards Dinner
- Parkinson’s in the Media

-----

Medtronic and Eli Lilly recently announced a collaboration to research and develop a new approach to treating Parkinson’s disease that involves delivering a potential new medicine to the brain using an implantable drug delivery system.  According to their press release, “the goal of the collaboration is to develop a therapeutic approach for Parkinson’s disease that combines the strengths of Lilly’s biologic, a modified form of glial cell derived neurotrophic factor (GDNF), with Medtronic’s implantable drug infusion system technology.”

This research, which follows up on earlier research done by Amgen, is exciting news for the Parkinson’s community.  You can read the press release Medtronic and Eli Lilly issued on April 26, 2011, as well as this Wall Street Journal story about the new research.  We’ll continue to share information as we learn more about their work.